Intuit Inc. vs Nuwellis Inc — how do they compare? Intuit Inc. trades at $332.01 (market cap $92.03B), while Nuwellis Inc trades at $1.49 (market cap $542.80K). The key difference: Intuit Inc. is far larger — about 169546.8× Nuwellis Inc's market cap, and Intuit Inc. pays a 1.43% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| INTU | NUWE | |
|---|---|---|
Market Cap | $92.03B | $542.80K |
Sector | Technology | Technology |
52-Week High | $717.21 | $220.50 |
52-Week Low | $255.07 | $1.42 |
Enterprise Value | $90.49B | -$1.27M |
Dividend Yield | 1.43% | — |
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $334.43, up 2.82% today, with a bullish technical signal from moving averages and strong fundamental performance. Recent earnings beats, including Q1 2026 EPS of $12.8 versus $12.57 expected, highlight robust profitability. However, the stock faces headwinds from legal investigations into pricing disclosures and a recent 20% drop, as reported by Forbes on June 2, 2026.
The outlook is mixed: analyst consensus targets $402.26 (66.7% buy ratings), but legal risks and overbought RSI levels near 74.42 suggest caution. Revenue growth to $20.9B in 2026 and a high net margin of 21.9% support long-term value, yet near-term volatility may persist due to sentiment shifts.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →